Harpoon Therapeutics, Inc

144 articles about Harpoon Therapeutics, Inc

• Harpoon Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

  8/5/2021

  Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

• Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences - Aug 03, 2021

  8/3/2021

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences

• Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform

  6/4/2021

  Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment duration All four clinical programs demonstrate half-life extension, target engagement and T cell activation Cytokine release syndrome observed and manageable, with low incidence of severe CRS Management to host webcast and conference call to review the interim data presented at ASCO and provide a pipeline update today at 4 p.m. ET /1 p.m. PT

• Harpoon Therapeutics Presents Updated Interim Clinical Data for the PSMA-targeting TriTAC® HPN424 at the 2021 ASCO Annual Meeting

  6/4/2021

  Harpoon Therapeutics, Inc. (NASDAQ: HARP), today presented interim data from the ongoing dose-escalation portion of a Phase 1/2a trial for HPN424 in patients with metastatic castration-resistant prostate cancer (mCRPC) at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

• Harpoon Therapeutics to Present Updated Interim Clinical Data for TriTAC® HPN424 at the 2021 ASCO Annual MeetingManagement to host webcast and conference call to provide a pipeline update at 4 p.m. ET / 1 p.m. PT on June 4, 2021

  5/19/2021

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that updated interim Phase 1 data for HPN424 for prostate cancer will be presented at the 2021 American Society of Clinical Oncology Annual Meeting beginning on June 4,2021.

• Harpoon Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

  5/6/2021

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

• Harpoon Therapeutics to Participate in Truist Securities Life Sciences Summit

  4/28/2021

  Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Jerry McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit.

• Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021

  4/10/2021

  Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced the availability of three poster presentations at the American Association for Cancer Research Annual Meeting.

• Harpoon Therapeutics Appoints Experienced Biotech Leader Alan Colowick, M.D., to Board of Directors

  3/24/2021

  Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Alan Colowick, M.D., to its board of directors. Dr. Colowick is an experienced biotech leader and has served in numerous executive and board roles.

• Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021

  3/11/2021

  Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting

• Harpoon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

  3/10/2021

  Provided positive update on its four TriTAC® clinical trials, including a confirmed partial response for HPN424 in the treatment of metastatic castration-resistant prostate cancer

• Harpoon Therapeutics to Participate in 33rd Annual Roth Conference

  3/9/2021

  Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Jerry McMahon, Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the 33 rd Annual Roth Conference.

• Harpoon Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Corporate Update

  3/4/2021

  Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it will report fourth quarter and full year 2020 financial results and provide a corporate update on Wednesday, March 10, 2021.

• Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference

  2/17/2021

  Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 10 th Annual Global Healthcare Conference. The discussion will take place on Wednesday, February 24, 2021 at 4:20 p.m. ET (1:20 p.m. PT).

• Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma

  1/13/2021

  Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN217 for the treatment of multiple myeloma

• Harpoon Therapeutics Announces Closing of Public Offering of Common StockUnderwriters Fully Exercise Option to Purchase Additional Shares

  1/11/2021

  Harpoon Therapeutics, Inc. (Nasdaq: HARP) announced today the closing of its underwritten public offering of 6,764,704 shares of its common stock, which includes 882,352 shares sold upon the underwriters’ full exercise of their option to purchase additional shares, resulting in aggregate gross proceeds of approximately $115.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Harpoon T

• 

  Clinical Catch-Up: January 4-8

  1/11/2021

  The new year began with a fairly low level of clinical trial news. Here’s a look.

• Harpoon Therapeutics Announces Pricing of Public Offering of Common Stock - Jan 07, 2021

  1/7/2021

  Harpoon Therapeutics, Inc., announced the pricing of an underwritten public offering of 5,882,352 shares of its common stock at a price to the public of $17.00 per share.

• Harpoon Therapeutics Announced Proposed Public Offering of Common Stock

  1/6/2021

  Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that it has commenced an underwritten public offering of its common stock. In connection with the offering, Harpoon Therapeutics intends to grant the underwriters in the offering a 30-day option to purchase up to an additional 15 percent of the number of shares sold. Harpoon Therapeutics p

• Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated TumorsHPN328, Harpoon’s fourth TriTAC® T cell engager, enters clinical development

  1/4/2021

  Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the first patient has been dosed with HPN328, a delta like ligand 3- (DLL3) targeting TriTAC®, in a Phase 1/2 clinical trial as an investigational treatment of small cell lung cancer (SCLC) and other tumors associated with DLL3 expression